West Pharmaceutical Services, Inc. - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. West Pharmaceutical Services, Inc. is a global manufacturer of containment and delivery systems for injectable drugs. Effective in Q1 2026, the company renamed its "Contract-Manufactured Products" segment to West Vantage. The company operates two reportable segments: Proprietary Products and West Vantage.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $844.9 million | $698.0 million |
| Gross Profit | $296.4 million | $231.9 million |
| Gross Margin | 35.1% | 33.2% |
| Operating Profit | $177.1 million | $107.0 million |
| Net Income | $138.8 million | $89.8 million |
| Diluted EPS | $1.92 | $1.23 |
| Operating Cash Flow | $89.9 million | $129.4 million |
| Cash and Equivalents | $521.4 million | $404.2 million (Q1 2025) |
| Long-Term Debt | $202.8 million | $202.8 million (Dec 2025) |
| Working Capital | $1,152.8 million | $1,323.3 million (Dec 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 21.0% year-over-year, driven by a 15.3% organic increase. Proprietary Products sales rose 23.3% (17.5% organic), while West Vantage sales rose 11.6% (6.2% organic).
- Profitability: Operating profit surged 65.5% to $177.1 million. Adjusted operating profit (non-GAAP) was $181.0 million, compared to $125.0 million in Q1 2025.
- Restructuring Costs: Restructuring charges decreased significantly to $1.8 million in Q1 2026, compared to $16.4 million in Q1 2025.
- Tax Rate: The effective tax rate increased to 24.8% from 21.8%, primarily due to a one-time $12.0 million tax cost associated with an internal legal entity restructuring.
- Share Repurchases: The company repurchased 1.22 million shares for $297.6 million in Q1 2026, under a new $1.0 billion program authorized in February 2026.
Outlook, Risks, and Unusual Items
- SmartDose Sale: The company entered a definitive agreement in December 2025 to sell the SmartDose 3.5mL On-Body Delivery System to AbbVie for approximately $112.5 million. Closing is expected in mid-2026. Assets related to this sale are classified as "held for sale."
- Legal Proceedings: A securities class action lawsuit was filed in May 2025 alleging violations of the Securities Exchange Act. The company intends to vigorously defend the claims, which are currently in early stages.
- Macroeconomic Factors: Management is monitoring U.S. tariffs and trade restrictions, as well as geopolitical conflicts in the Middle East affecting petrochemical costs. Management does not currently expect these to have a material impact on 2026 results.
- Capital Allocation: The company continues to prioritize share repurchases and dividends. A quarterly dividend of $0.22 per share was declared.
Investor Verification Checklist
- Verify the closing timeline and final consideration for the SmartDose sale to AbbVie.
- Monitor the status of the securities class action lawsuit filed in May 2025.
- Assess the impact of the one-time $12.0 million tax cost on future effective tax rate projections.
- Review the organic growth drivers in the Proprietary Products segment, specifically demand for high-value components.
- Track the execution of the new $1.0 billion share repurchase program and its impact on cash reserves.